← Leaderboards
Neil Johnson
Research Inst Of Fox Chase Can Ctr
$9,155,684
Attributed
$9,155,684
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,155,684 · 6
By mechanism
R01$8,676,222 · 4
R21$427,062 · 1
P30$52,400 · 1
Top collaborators
No co-investigators on record.
Most similar at Research Inst Of Fox Chase Can Ctr
Same institution · by research overlap
- Eric Andrew Ross$4,618,489
- Erica A Golemis$12,682,758
- Siddharth Balachandran$16,302,354
- Hossein Borghaei$897,858
- Johnathan R. Whetstine$5,607,229
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsBrca1 GeneDna RepairHomologous RecombinationCellsAllelesMalignant NeoplasmsMalignant Neoplasm Of OvaryMalignant Breast NeoplasmMutationBrca1 MutationUnited StatesBreastMediatingCessation Of LifeInsightBrca2 MutationBrca2 GeneDna Double Strand BreakDefectExperimental StudyDna Repair PathwayMolecularMutant
Grant awards (24)
Compensatory Mechanisms that Promote Homologous Recombination in BRCA1 Mutant Cancers$470,000
R01 · FY2025 · CA · contact PI
Assessing DNA polymerase theta as a therapeutic target in BRCA1 mutant cancer$430,050
R01 · FY2025 · CA · contact PI
Biological Imaging Facility$52,400
P30 · FY2025 · CA · contact PI
Compensatory Mechanisms that Promote Homologous Recombination in BRCA1 Mutant Cancers$470,000
R01 · FY2024 · CA · contact PI
Assessing DNA polymerase theta as a therapeutic target in BRCA1 mutant cancer$408,548
R01 · FY2024 · CA · contact PI
The role of microhomology-mediated end joining in Fanconi anemia pathogenesis$467,500
R01 · FY2023 · HL · contact PI
Assessing DNA polymerase theta as a therapeutic target in BRCA1 mutant cancer$421,449
R01 · FY2023 · CA · contact PI
Dissecting BRCA1-PALB2 Activity in DNA Repair and Development$386,563
R01 · FY2023 · GM · contact PI
Assessing DNA Polymerase Theta as a Therapeutic Target in BRCA1 Mutant Cancer$200,000
R01 · FY2023 · CA · contact PI
The role of microhomology-mediated end joining in Fanconi anemia pathogenesis$454,090
R01 · FY2022 · HL · contact PI
Assessing DNA polymerase theta as a therapeutic target in BRCA1 mutant cancer$430,050
R01 · FY2022 · CA · contact PI
Dissecting BRCA1-PALB2 Activity in DNA Repair and Development$408,313
R01 · FY2022 · GM · contact PI
The role of microhomology-mediated end joining in Fanconi anemia pathogenesis$467,500
R01 · FY2021 · HL · contact PI
Dissecting BRCA1-PALB2 Activity in DNA Repair and Development$428,989
R01 · FY2021 · GM · contact PI
Compensatory mechanisms that promote homologous recombination in BRCA1 mutant cancers$427,763
R01 · FY2021 · CA · contact PI
Dissecting BRCA1-PALB2 Activity in DNA Repair and Development$229,000
R01 · FY2021 · GM · contact PI
The role of microhomology-mediated end joining in Fanconi anemia pathogenesis$467,500
R01 · FY2020 · HL · contact PI
Dissecting BRCA1-PALB2 Activity in DNA Repair and Development$428,989
R01 · FY2020 · GM · contact PI
Compensatory mechanisms that promote homologous recombination in BRCA1 mutant cancers$427,763
R01 · FY2020 · CA · contact PI
Compensatory mechanisms that promote homologous recombination in BRCA1 mutant cancers$414,929
R01 · FY2019 · CA · contact PI
Compensatory mechanisms that promote homologous recombination in BRCA1 mutant cancers$418,613
R01 · FY2018 · CA · contact PI
Compensatory mechanisms that promote homologous recombination in BRCA1 mutant cancers$418,613
R01 · FY2017 · CA · contact PI
Identifying BRCA1 protein variants that provide resistance to therapy$232,943
R21 · FY2016 · CA · contact PI
Identifying BRCA1 protein variants that provide resistance to therapy$194,119
R21 · FY2015 · CA · contact PI